Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Liposomal Bupivacaine · Exparel, Marcaine

Small molecule · Inhibitor of voltage-gated sodium channel (neuronal membrane) · developed by Pacira Pharms

Approved FDA, Oct 2011
PCRX Developer
9 Registered trials

What is Liposomal Bupivacaine?

Liposomal bupivacaine is a liposome-encapsulated formulation of bupivacaine, an amide-type long-acting local anesthetic. Bupivacaine reversibly binds sodium ion channels in the neuronal membrane, inhibiting depolarization and nerve impulse conduction, and liposomal delivery prolongs the duration of action. It is studied in postoperative pain, total knee arthroplasty, rotator cuff tear, hand and wrist injuries, and bunionectomy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Exparel, Marcaine, Sensorcaine, Exparel Forearm block
Drug type
Small molecule
Targets
voltage-gated sodium channel (neuronal membrane)
Mechanism
Inhibitor of voltage-gated sodium channel (neuronal membrane)
Pathways
nerve impulse conduction, membrane depolarization
Therapy area
Musculoskeletal
Developer
Pacira Pharms Inc (PCRX)
Also in trials of
HRTX
FDA status
Approved as Exparel, Marcaine, Sensorcaine (October 28, 2011), NDA022496 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 12, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07584915 Phase 4 Total Knee Arthroplasty Enrolling by invitation PCRX
NCT05730920 Phase 4 Adolescent Idiopathic Scoliosis Completed PCRX
NCT04102267 Phase 4 Analgesia Completed HRTX
NCT03290196 Phase 4 Rotator Cuff Tear Terminated PCRX
NCT02058303 Phase 4 Hand Injuries Terminated PCRX
NCT06077422 Phase 2/3 Pain, Postoperative Enrolling by invitation PCRX
NCT05157841 Phase 3 Bunionectomy Completed PCRX
NCT04117074 Phase 3 Surgery Completed PCRX
NCT05456490 Phase 1 Healthy Completed PCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Heart DiseasesOpioid UsePain, PostoperativePerioperative ComplicationTotal Knee ArthroplastyTotal Knee Arthroplasty RecoveryAdolescent Idiopathic ScoliosisAnalgesiaBunionectomyFinger InjuriesHallux ValgusHand InjuriesHealthyJuvenile Idiopathic Scoliosis

More from Pacira Pharms

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PCRX page.

Follow PCRX, the company behind Liposomal Bupivacaine

See PCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PCRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.